Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Sci Rep ; 10(1): 18845, 2020 11 02.
Article in English | MEDLINE | ID: mdl-33139857

ABSTRACT

22q11.2 Deletion Syndrome (22q11.2DS) is the most common microdeletion in humans, with a heterogenous clinical presentation including medical, behavioural and psychiatric conditions. Previous neuroimaging studies examining the neuroanatomical underpinnings of 22q11.2DS show alterations in cortical volume (CV), cortical thickness (CT) and surface area (SA). The aim of this study was to identify (1) the spatially distributed networks of differences in CT and SA in 22q11.2DS compared to controls, (2) their unique and spatial overlap, as well as (3) their relative contribution to observed differences in CV. Structural MRI scans were obtained from 62 individuals with 22q11.2DS and 57 age-and-gender-matched controls (aged 6-31). Using FreeSurfer, we examined differences in vertex-wise estimates of CV, CT and SA at each vertex, and compared the frequencies of vertices with a unique or overlapping difference for each morphometric feature. Our findings indicate that CT and SA make both common and unique contributions to volumetric differences in 22q11.2DS, and in some areas, their strong opposite effects mask differences in CV. By identifying the neuroanatomic variability in 22q11.2DS, and the separate contributions of CT and SA, we can start exploring the shared and distinct mechanisms that mediate neuropsychiatric symptoms across disorders, e.g. 22q11.2DS-related ASD and/or psychosis/schizophrenia.


Subject(s)
Brain Cortical Thickness , Brain/physiopathology , DiGeorge Syndrome/physiopathology , Schizophrenia/physiopathology , Adolescent , Adult , Brain/diagnostic imaging , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/physiopathology , Child , DiGeorge Syndrome/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Male , Psychiatric Status Rating Scales , Schizophrenia/diagnostic imaging , Surface Properties , Young Adult
2.
Cereb Cortex ; 29(8): 3655-3665, 2019 07 22.
Article in English | MEDLINE | ID: mdl-30272146

ABSTRACT

22q11.2 Deletion Syndrome (22q11.2DS) is a genetic condition associated with a high prevalence of neuropsychiatric conditions that include autism spectrum disorder (ASD). While evidence suggests that clinical phenotypes represent distinct neurodevelopmental outcomes, it remains unknown whether this translates to the level of neurobiology. To fractionate the 22q11.2DS phenotype on the level of neuroanatomy, we examined differences in vertex-wise estimates of cortical volume, surface area, and cortical thickness between 1) individuals with 22q11.2DS (n = 62) and neurotypical controls (n = 57) and 2) 22q11.2DS individuals with ASD symptomatology (n = 30) and those without (n = 25). We firstly observed significant differences in surface anatomy between 22q11.2DS individuals and controls for all 3 neuroanatomical features, predominantly in parietotemporal regions, cingulate and dorsolateral prefrontal cortices. We also established that 22q11.2DS individuals with ASD symptomatology were neuroanatomically distinct from 22q11.2DS individuals without ASD symptoms, particularly in brain regions that have previously been linked to ASD (e.g., dorsolateral prefrontal cortices and the entorhinal cortex). Our findings indicate that different clinical 22q11.2DS phenotypes, including those with ASD symptomatology, may represent different neurobiological subgroups. The spatially distributed patterns of neuroanatomical differences associated with ASD symptomatology in 22q11.2DS may thus provide useful information for patient stratification and the prediction of clinical outcomes.


Subject(s)
Autism Spectrum Disorder/diagnostic imaging , Brain/diagnostic imaging , DiGeorge Syndrome/diagnostic imaging , Adolescent , Adult , Autism Spectrum Disorder/etiology , Autism Spectrum Disorder/pathology , Autism Spectrum Disorder/psychology , Brain/pathology , Case-Control Studies , Child , DiGeorge Syndrome/complications , DiGeorge Syndrome/pathology , DiGeorge Syndrome/psychology , Entorhinal Cortex/diagnostic imaging , Entorhinal Cortex/pathology , Female , Gyrus Cinguli/diagnostic imaging , Gyrus Cinguli/pathology , Humans , Male , Organ Size , Parietal Lobe/diagnostic imaging , Parietal Lobe/pathology , Prefrontal Cortex/diagnostic imaging , Prefrontal Cortex/pathology , Temporal Lobe/diagnostic imaging , Temporal Lobe/pathology , Young Adult
3.
Transl Psychiatry ; 7(4): e1090, 2017 04 11.
Article in English | MEDLINE | ID: mdl-28398337

ABSTRACT

Autism spectrum conditions (ASC) are more prevalent in males than females. The biological basis of this difference remains unclear. It has been postulated that one of the primary causes of ASC is a partial disconnection of the frontal lobe from higher-order association areas during development (that is, a frontal 'disconnection syndrome'). Therefore, in the current study we investigated whether frontal connectivity differs between males and females with ASC. We recruited 98 adults with a confirmed high-functioning ASC diagnosis (61 males: aged 18-41 years; 37 females: aged 18-37 years) and 115 neurotypical controls (61 males: aged 18-45 years; 54 females: aged 18-52 years). Current ASC symptoms were evaluated using the Autism Diagnostic Observation Schedule (ADOS). Diffusion tensor imaging was performed and fractional anisotropy (FA) maps were created. Mean FA values were determined for five frontal fiber bundles and two non-frontal fiber tracts. Between-group differences in mean tract FA, as well as sex-by-diagnosis interactions were assessed. Additional analyses including ADOS scores informed us on the influence of current ASC symptom severity on frontal connectivity. We found that males with ASC had higher scores of current symptom severity than females, and had significantly lower mean FA values for all but one tract compared to controls. No differences were found between females with or without ASC. Significant sex-by-diagnosis effects were limited to the frontal tracts. Taking current ASC symptom severity scores into account did not alter the findings, although the observed power for these analyses varied. We suggest these findings of frontal connectivity abnormalities in males with ASC, but not in females with ASC, have the potential to inform us on some of the sex differences reported in the behavioral phenotype of ASC.


Subject(s)
Autism Spectrum Disorder/diagnostic imaging , Autism Spectrum Disorder/pathology , Diffusion Tensor Imaging , Frontal Lobe/diagnostic imaging , Frontal Lobe/pathology , Neural Pathways/diagnostic imaging , Neural Pathways/pathology , Adolescent , Adult , Case-Control Studies , Female , Humans , Male , Middle Aged , Sex Factors , Young Adult
5.
Transl Psychiatry ; 3: e279, 2013 07 09.
Article in English | MEDLINE | ID: mdl-23838890

ABSTRACT

Dysfunctional glutamatergic neurotransmission has been implicated in autism spectrum disorder (ASD). However, relatively few studies have directly measured brain glutamate in ASD adults, or related variation in glutamate to clinical phenotype. We therefore set out to investigate brain glutamate levels in adults with an ASD, comparing these to healthy controls and also comparing results between individuals at different points on the spectrum of symptom severity. We recruited 28 adults with ASD and 14 matched healthy controls. Of those with ASD, 15 fulfilled the 'narrowly' defined criteria for typical autism, whereas 13 met the 'broader phenotype'. We measured the concentration of the combined glutamate and glutamine signal (Glx), and other important metabolites, using proton magnetic resonance spectroscopy in two brain regions implicated in ASD--the basal ganglia (including the head of caudate and the anterior putamen) and the dorsolateral prefrontal cortex--as well as in a parietal cortex 'control' region. Individuals with ASD had a significant decrease (P<0.001) in concentration of Glx in the basal ganglia, and this was true in both the 'narrow' and 'broader' phenotype. Also, within the ASD sample, reduced basal ganglia Glx was significantly correlated with increased impairment in social communication (P=0.013). In addition, there was a significant reduction in the concentration of other metabolites such as choline, creatine (Cr) and N-acetylaspartate (NAA) in the basal ganglia. In the dorsolateral prefrontal cortex, Cr and NAA were reduced (P<0.05), although Glx was not. There were no detectable differences in Glx, or any other metabolite, in the parietal lobe control region. There were no significant between-group differences in age, gender, IQ, voxel composition or data quality. In conclusion, individuals across the spectrum of ASD have regionally specific abnormalities in subcortical glutamatergic neurotransmission that are associated with variation in social development.


Subject(s)
Brain Chemistry , Child Development Disorders, Pervasive/metabolism , Glutamic Acid/analysis , Glutamine/analysis , Adult , Asperger Syndrome/metabolism , Autistic Disorder , Basal Ganglia/chemistry , Case-Control Studies , Child , Female , Humans , Magnetic Resonance Spectroscopy , Male , Prefrontal Cortex/chemistry , Severity of Illness Index
6.
Psychol Med ; 43(2): 401-11, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22617495

ABSTRACT

BACKGROUND: Children with conduct disorder (CD) are at increased risk of developing antisocial personality disorder (ASPD) and psychopathy in adulthood. The biological basis for this is poorly understood. A preliminary diffusion tensor magnetic resonance imaging (DT-MRI) study of psychopathic antisocial adults reported significant differences from controls in the fractional anisotropy (FA) of the uncinate fasciculus (UF), a white-matter tract that connects the amygdala to the frontal lobe. However, it is unknown whether developmental abnormalities are present in the UF of younger individuals with CD. METHOD: We used DT-MRI tractography to investigate, for the first time, the microstructural integrity of the UF in adolescents with CD, and age-related differences in this tract. We compared FA and perpendicular diffusivity of the UF in 27 adolescents with CD and 16 healthy controls (12 to 19 years old) who did not differ significantly in age, IQ or substance use history. To confirm that these findings were specific to the UF, the same measurements were extracted from two non-limbic control tracts. Participants in the CD group had a history of serious aggressive and violent behaviour, including robbery, burglary, grievous bodily harm and sexual assault. RESULTS: Individuals with CD had a significantly increased FA (p = 0.006), and reduced perpendicular diffusivity (p = 0.002), in the left UF. Furthermore, there were significant age-related between-group differences in perpendicular diffusivity of the same tract (Z obs = 2.40, p = 0.01). Controls, but not those with CD, showed significant age-related maturation. There were no significant between-group differences in any measure within the control tracts. CONCLUSIONS: Adolescents with CD have significant differences in the 'connectivity' and maturation of UF.


Subject(s)
Conduct Disorder/pathology , Frontal Lobe/ultrastructure , Limbic System/ultrastructure , Adolescent , Adolescent Development , Adult , Amygdala/growth & development , Amygdala/ultrastructure , Analysis of Variance , Anisotropy , Case-Control Studies , Child , Child Development , Conduct Disorder/psychology , Diffusion Tensor Imaging/methods , Frontal Lobe/growth & development , Humans , Limbic System/growth & development , Male , Nerve Fibers, Myelinated/ultrastructure , Psychiatric Status Rating Scales , Young Adult
7.
Autism Res ; 5(1): 3-12, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21948742

ABSTRACT

It has been proposed that people with autism spectrum disorder (ASD) have abnormal morphometry and development of the amygdala and hippocampus (AH). However, previous reports are inconsistent, perhaps because they included people of different ASD diagnoses, ages, and health. We compared, using magnetic resonance imaging, the in vivo anatomy of the AH in 32 healthy individuals with Asperger syndrome (12-47 years) and 32 healthy controls who did not differ significantly in age or IQ. We measured bulk (gray + white matter) volume of the AH using manual tracing (MEASURE). We first compared the volume of AH between individuals with Asperger syndrome and controls and then investigated age-related differences. We compared differences in anatomy before, and after, correcting for whole brain size. There was no significant between group differences in whole brain volume. However, individuals with Asperger syndrome had a significantly larger raw bulk volume of total (P<0.01), right (P<0.01), and left amygdala (P<0.05); and when corrected for overall brain size, total (P<0.05), and right amygdala (P<0.01). There was a significant group difference in aging of left amygdala; controls, but not individuals with Asperger syndrome, had a significant age-related increase in volume (r = 0.486, P<0.01, and r = 0.007, P = 0.97, z = 1.995). There were no significant group differences in volume or age-related effects in hippocampus. Individuals with Asperger syndrome have significant differences from controls in bulk volume and aging of the amygdala.


Subject(s)
Aging , Amygdala/pathology , Asperger Syndrome/pathology , Child Development Disorders, Pervasive/pathology , Hippocampus/pathology , Magnetic Resonance Imaging/methods , Adolescent , Adult , Age Factors , Amygdala/anatomy & histology , Brain Mapping/methods , Child , Hippocampus/anatomy & histology , Humans , Imaging, Three-Dimensional/methods , Middle Aged , United Kingdom , Young Adult
8.
Psychoneuroendocrinology ; 35(7): 987-1000, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20102786

ABSTRACT

Women have an increased risk of developing Alzheimer's Dementia (AD) compared to men. It has been postulated that this risk may be modulated by a reduction in the neuroprotective effects of estrogen on the brain in the early postmenopausal period. This view is supported by, for example, findings that ovariectomy in younger women (i.e. prior to menopause) significantly increases the risk for the development of memory problems and AD in later life. However, the biological basis underlying these cognitive changes is still poorly understood. Our aim in the current study was to understand the interactive effects of acute, pharmacological-induced menopause (after Gonadotropin Hormone Releasing Hormone agonist (GnRHa) treatment) and scopolamine (a cholinergic antagonist used to model the memory decline associated with aging and AD) on brain functioning. To this end we used fMRI to study encoding during a Delayed Match to Sample (DMTS) (visual working memory) task. We report a relative attenuation in BOLD response brought about by scopolamine in regions that included bilateral prefrontal cortex and the left parahippocampal gyrus. Further, this was greater in women post-GnRHa than in women whose ovaries were functional. Our results also indicate that following pharmacological-induced menopause, cholinergic depletion produces a more significant behavioural deficit in overall memory performance, as manifest by increased response time. These findings suggest that acute loss of ovarian hormones exacerbate the effects of cholinergic depletion on a memory-related, behavioural measure, which is dependent on fronto-temporal brain regions. Overall, our findings point to a neural network by which acute loss of ovarian function may interact to negatively impact encoding.


Subject(s)
Acetylcholine/physiology , Alzheimer Disease/physiopathology , Gonadotropin-Releasing Hormone/physiology , Memory, Short-Term/physiology , Menopause/physiology , Ovary/physiology , Space Perception/physiology , Acetylcholine/antagonists & inhibitors , Adult , Aging/physiology , Brain Mapping , Cholinergic Antagonists/pharmacology , Female , Gonadotropin-Releasing Hormone/agonists , Gonadotropin-Releasing Hormone/analogs & derivatives , Gonadotropin-Releasing Hormone/pharmacology , Humans , Magnetic Resonance Imaging , Memory, Short-Term/drug effects , Menopause/drug effects , Middle Aged , Ovary/drug effects , Parahippocampal Gyrus/drug effects , Parahippocampal Gyrus/physiology , Prefrontal Cortex/drug effects , Prefrontal Cortex/physiology , Scopolamine/pharmacology
9.
Mol Psychiatry ; 14(10): 946-53, 907, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19506560

ABSTRACT

Psychopathy is strongly associated with serious criminal behaviour (for example, rape and murder) and recidivism. However, the biological basis of psychopathy remains poorly understood. Earlier studies suggested that dysfunction of the amygdala and/or orbitofrontal cortex (OFC) may underpin psychopathy. Nobody, however, has ever studied the white matter connections (such as the uncinate fasciculus (UF)) linking these structures in psychopaths. Therefore, we used in vivo diffusion tensor magnetic resonance imaging (DT-MRI) tractography to analyse the microstructural integrity of the UF in psychopaths (defined by a Psychopathy Checklist Revised (PCL-R) score of > or = 25) with convictions that included attempted murder, manslaughter, multiple rape with strangulation and false imprisonment. We report significantly reduced fractional anisotropy (FA) (P<0.003), an indirect measure of microstructural integrity, in the UF of psychopaths compared with age- and IQ-matched controls. We also found, within psychopaths, a correlation between measures of antisocial behaviour and anatomical differences in the UF. To confirm that these findings were specific to the limbic amygdala-OFC network, we also studied two 'non-limbic' control tracts connecting the posterior visual and auditory areas to the amygdala and the OFC, and found no significant between-group differences. Lastly, to determine that our findings in UF could not be totally explained by non-specific confounds, we carried out a post hoc comparison with a psychiatric control group with a past history of drug abuse and institutionalization. Our findings remained significant. Taken together, these results suggest that abnormalities in a specific amygdala-OFC limbic network underpin the neurobiological basis of psychopathy.


Subject(s)
Antisocial Personality Disorder/pathology , Criminals/psychology , Nerve Fibers, Myelinated/pathology , Neural Pathways/pathology , Adult , Diffusion Magnetic Resonance Imaging , Humans , Male , Middle Aged , Models, Neurological , Substance-Related Disorders/pathology
10.
Horm Behav ; 55(1): 41-9, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18809406

ABSTRACT

Recent evidence suggests that loss of ovarian function following ovariectomy is a risk factor for Alzheimer's disease (AD); however, the biological basis of this risk remains poorly understood. We carried out an fMRI study into the interaction between loss of ovarian function (after Gonadotropin Hormone Releasing Hormone agonist (GnRHa) treatment) and scopolamine (a cholinergic antagonist used to model the memory decline associated with aging and AD). Behaviorally, cholinergic depletion produced a deficit in verbal recognition performance in both GnRHa-treated women and wait list controls, but only GnRHa-treated women made more false positive errors with cholinergic depletion. Similarly, cholinergic depletion produced a decrease in activation in the left inferior frontal gyrus (LIFG; Brodmann area 45)--a brain region implicated in retrieving word meaning--in both groups, and activation in this area was further reduced following GnRHa treatment. These findings suggest biological mechanisms through which ovarian hormone suppression may interact with the cholinergic system and the LIFG. Furthermore, this interaction may provide a useful model to help explain reports of increased risk for cognitive decline and AD in women following ovariectomy.


Subject(s)
Brain/physiology , Cholinergic Antagonists/pharmacology , Gonadotropin-Releasing Hormone/agonists , Ovary/physiology , Recognition, Psychology , Scopolamine/pharmacology , Adult , Analysis of Variance , Brain/drug effects , Brain Mapping , Female , Gonadotropin-Releasing Hormone/blood , Humans , Magnetic Resonance Imaging , Middle Aged , Recognition, Psychology/drug effects , Recognition, Psychology/physiology , Semantics
11.
Climacteric ; 10 Suppl 2: 97-104, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17882683

ABSTRACT

Many women complain of memory and other cognitive/emotional difficulties at times that are associated with changes in estrogen levels. However, the biological mechanisms through which estrogen may exert these effects remain poorly understood. The effect of estrogen treatment on cognition and brain function in healthy women, and those with Alzheimer's disease, is controversial. Here we review the evidence that, in healthy women, estrogen affects the dopaminergic, serotonergic, and cholinergic systems, and brain regions crucial to higher cognitive function and mood. We will also present results from recent in vivo randomized-controlled neuroimaging experiments in our laboratory demonstrating that, in young females, and those in mid-life: (1) brain function is modulated by normal variation in ovarian function; (2) acute loss of ovarian hormones increases neuronal membrane breakdown; and (3) acute suppression of ovarian function is associated with reduced activation of brain regions critical to memory.


Subject(s)
Alzheimer Disease/prevention & control , Brain/drug effects , Cognition Disorders/prevention & control , Estrogen Replacement Therapy , Estrogens/pharmacology , Aging/drug effects , Cognition/drug effects , Female , Humans , Menopause/drug effects , Nervous System Diseases/prevention & control , Randomized Controlled Trials as Topic
12.
J Neuroendocrinol ; 19(1): 1-6, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17184480

ABSTRACT

Many women complain of memory and other cognitive difficulties at times that are associated with changes in ovarian steroid levels. However, the biological mechanisms through which ovarian steroids exert these effects remains poorly understood. Furthermore, the effect of hormone therapy, especially oestrogen therapy, on cognition and brain function in healthy women, and its role in the prevention of Alzheimer's disease, remains controversial. Here, we review the evidence that, in healthy women, ovarian steroids/oestrogen affects brain regions crucial to higher cognitive function at the macroscopic, microscopic, functional and neurotransmitter levels.


Subject(s)
Aging , Brain/drug effects , Brain/physiology , Cognition/physiology , Estrogens/pharmacology , Cognition/drug effects , Dementia/prevention & control , Female , Humans , Menopause/physiology
13.
Psychoneuroendocrinology ; 29(10): 1309-16, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15288710

ABSTRACT

Females have a higher prevalence than men of neuropsychiatric disorders in which dopaminergic abnormalities play a prominent role, e.g. very late-onset schizophrenia and Parkinson's disease (PD). The biological basis of these sex differences is unknown but may include modulation of the dopaminergic system by sex hormones, as there is preliminary evidence that estrogen modulates treatment response in these disorders. Furthermore, sex differences in dopamine-mediated cognitive decline suggest estrogen may also play a role in healthy aging. However, the effects of estrogen on the dopaminergic system are poorly understood, and nobody has examined the effect of long-term estrogen therapy (ET) on this system. We compared dopaminergic responsivity (growth hormone (GH) response to apomorphine) in post-menopausal women on ET to women who were ET-naïve. GH response to subcutaneous apomorphine (0.005 mg/kg) was measured in two groups of healthy post-menopausal women aged between 55 and 70 years: those taking ET (n = 13) and those who had never taken ET (n = 13). Neither group was taking any other medication. GH was measured at 15 min intervals from -30 min before administration of apomorphine to 90 min post-administration. GH response was measured in two ways: area under the curve (AUC) and maximum response over baseline (GH). There were no between-group differences in demographic or baseline variables. The ET treated women had a significantly greater (p = 0.03) AUC than ET naïve women (mean +/- S.D.; 5.3 +/- 4.7 vs. 2.6 +/- 2.3). However, (GH) did not differ significantly between groups (6.1 mU/l +/- 6.2 vs. 2.7 mU/l +/- S.D. = 4.1). Also, analysis of GH response over time revealed a significant main effect of time (p < 0.0005), and a group by time interaction (p = 0.004) , but no significant main effect of group. Our results suggest that ET may enhance dopaminergic responsivity in post-menopausal women. Estrogen deficiency following menopause may partly explain age and gender differences in late-onset neuropsychiatric disorders.


Subject(s)
Dopamine/metabolism , Estrogen Replacement Therapy , Estrogens/physiology , Human Growth Hormone/blood , Postmenopause/physiology , Aged , Aging/physiology , Analysis of Variance , Apomorphine/pharmacology , Area Under Curve , Brain/drug effects , Brain/metabolism , Dopamine Agonists/pharmacology , Female , Human Growth Hormone/drug effects , Humans , Middle Aged , Pilot Projects , Postmenopause/drug effects , Stimulation, Chemical , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...